Who Paid My Doc
Nicholas Wysham
Pulmonary Disease Vancouver, WA Medical Doctor
NPI 1144464496 CMS profile 822856
700 Ne 87Th Ave, Suite 250, Vancouver, WA 98664
General payments
$116,969
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$79,973
Through program year 2025, Nicholas Wysham of Vancouver, WA is reported in the CMS Open Payments database as having received $116,969 across 193 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $79,973 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,696 | 10 | |
| 2024 | General | $6,710 | 15 | |
| 2023 | General | $36,719 | 65 | |
| 2022 | General | $67,202 | 72 | |
| 2021 | General | $3,204 | 15 | |
| 2020 | General | $15 | 1 | |
| 2019 | General | $1,423 | 15 |
Beside peers
- Nicholas Wysham
- Pulmonary Disease median
- Middle half of Pulmonary Disease
- National median
In program year 2025, general payments to Nicholas Wysham were reported at $1,696. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.
Show as a table
| Year | Nicholas Wysham | Pulmonary Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,423 | $377 | $109–$1,340 | $163 |
| 2020 | $15 | $230 | $56–$907 | $114 |
| 2021 | $3,204 | $269 | $68–$1,072 | $132 |
| 2022 | $67,202 | $390 | $100–$1,457 | $149 |
| 2023 | $36,719 | $419 | $114–$1,659 | $160 |
| 2024 | $6,710 | $476 | $123–$1,818 | $164 |
| 2025 | $1,696 | $500 | $124–$1,893 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
1,093
Drug cost
$571,376
Branded share of claims
77.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 185 | $187,086 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 87 | $99,331 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 63 | $63,577 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 58 | $56,181 | |
| Dupixent Syringe Dupilumab | Brand | 14 | $52,021 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 60 | $22,633 | |
| Dulera Mometasone/Formoterol | Brand | 38 | $21,047 | |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 50 | $14,159 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 21 | $13,365 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 15 | $13,191 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 64 billing codesPaid by Medicare
$53,096
Medicare patients
175
Services billed
935
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| COPD | 50% | |
| Arthritis | 42% | |
| Ischemic heart disease | 33% | |
| Diabetes | 28% | |
| Cancer | 28% | |
| Atrial fibrillation | 26% | |
| Heart failure | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg J7614 | Office | 13 | 14 | $0 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 | Office | 15 | 16 | $0 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
193 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pulmonary Disease in Washington
Related records
Pulmonary Disease in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Pulmonary Disease
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.